Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis

@inproceedings{Beilman2016RealLifeTP,
  title={Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis},
  author={Candace L Beilman and Nguyen Xuan Thanh and Victoria Y. L. Ung and Christopher Ma and Karen Wong and Karen Ivy Kroeker and Thomas K. M. Lee and Haili Wang and Arto Ohinmaa and Phil Jacobs and Brendan Halloran and Richard N Fedorak},
  booktitle={Canadian journal of gastroenterology & hepatology},
  year={2016}
}
Background. Adalimumab is effective for the maintenance of remission in patients with moderate-to-severe ulcerative colitis (UC). Currently, biologic therapies are used in cases where patients fail conventional medical therapies. If biologic therapies are not available, patients often choose to remain in an unwell state rather than undergo colectomy. Objective. The aim of the study was to evaluate the cost-effectiveness of adalimumab in patients with UC where adalimumab was readily available… CONTINUE READING